EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hansa Biopharma AB's enterprise value is kr3,160.1 Mil.
Hansa Biopharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-697.1 Mil. Therefore, Hansa Biopharma AB's EV-to-EBITDA for today is -4.53.
The historical rank and industry rank for Hansa Biopharma AB's EV-to-EBITDA or its related term are showing as below:
OSTO:HNSA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -67.67 Med: -18.61 Max: -1.53
Current: -4.55
During the past 13 years, the highest EV-to-EBITDA of Hansa Biopharma AB was -1.53. The lowest was -67.67. And the median was -18.61.
OSTO:HNSA's EV-to-EBITDA is ranked worse than 100% of 446
companies
in the Biotechnology industry
Industry Median: 10.33
vs OSTO:HNSA: -4.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Hansa Biopharma AB EV-to-EBITDA Historical Data
The historical data trend for Hansa Biopharma AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hansa Biopharma AB's EV-to-EBITDA
For the Biotechnology subindustry, Hansa Biopharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's EV-to-EBITDA falls into.
Hansa Biopharma AB's current Enterprise Value is kr3,160.1 Mil.
Hansa Biopharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-697.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (OSTO:HNSA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Hansa Biopharma AB's PE Ratio for today is calculated as:
Hansa Biopharma AB's share price for today is kr43.62.
Hansa Biopharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Hansa Biopharma AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Hansa Biopharma AB (OSTO:HNSA) Business Description
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:HNSA has been successfully added to your 